0000885725-24-000011.txt : 20240131 0000885725-24-000011.hdr.sgml : 20240131 20240131063220 ACCESSION NUMBER: 0000885725-24-000011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240131 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24580564 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20240131.htm 8-K bsx-20240131
0000885725false00008857252024-01-312024-01-310000885725us-gaap:CommonStockMember2024-01-312024-01-310000885725bsx:SeniorNotedue2027Member2024-01-312024-01-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549
_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
_____________________________________________________________________


Date of Report (Date of earliest event reported): January 31, 2024

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240
(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                    01752-1234
        (Address of Principal Executive Offices)                          (Zip Code)

508 683-4000
(Registrant's telephone number, including area code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par value per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐





ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


ITEM 9.01.     FINANCIAL STATEMENTS AND EXHIBITS.

(d)  Exhibits


Exhibit No.        Description


104            Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
            document






































SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                
Date:January 31, 2024BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson
Susan Thompson
Vice President, Chief Corporate Counsel, and Assistant Secretary


 EX-99.1 2 q42023earningsrelease.htm EX-99.1 Q4 2023 EARNINGS RELEASE Document

imagea.jpg

FOR IMMEDIATE RELEASE

Boston Scientific Announces Results for
Fourth Quarter and Full Year 2023

Marlborough, Mass. (January 31, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.

For the full year 2023, the company generated net sales of $14.240 billion, growing 12.3 percent on a reported basis, 13.1 percent on an operational1 basis and 12.3 percent on an organic2 basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.570 billion or $1.07 per share, compared to $642 million or $0.45 per share a year ago, and delivered full year adjusted3 EPS of $2.05, compared to $1.71 a year ago.

“I am grateful to our global team, and proud of our exceptional results in 2023,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “We are excited about our future and long-range plans as we deliver on our mission to transform patient lives.”


Fourth quarter financial results and recent developments:

•Reported net sales of $3.725 billion, representing an increase of 14.9 percent on a reported basis, compared to the company's guidance range of 9 to 11 percent; 14.5 percent on an operational basis; and 13.6 percent on an organic basis, compared to the company's guidance range of 8 to 10 percent, all compared to the prior year period.

•Reported GAAP net income attributable to Boston Scientific common stockholders of $0.34 per share, compared to the company's guidance range of $0.26 to $0.30 per share, and achieved adjusted EPS of $0.55 per share, compared to the guidance range of $0.49 to $0.52 per share.

•Achieved the following net sales growth in each reportable segment, compared to the prior year period:
◦MedSurg: 11.1 percent reported, 10.5 percent operational and 8.9 percent organic
◦Cardiovascular: 13.9 percent reported, 13.8 percent operational and 13.3 percent organic

•Achieved the following net sales growth in each region, compared to the prior year period:
◦United States (U.S.): 11.4 percent reported and operational
◦Europe, Middle East and Africa (EMEA): 14.0 percent reported and 11.6 percent operational
◦Asia-Pacific (APAC): 14.8 percent reported and 17.0 percent operational
◦Latin America and Canada (LACA): 20.8 percent reported and 14.6 percent operational
◦Emerging Markets4: 16.3 percent reported and 18.7 percent operational

•Received U.S. Food and Drug Administration (FDA) approval of the FARAPULSE™ Pulsed Field Ablation (PFA) System for the isolation of pulmonary veins in the treatment of drug-resistant, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF).

•Commenced enrollment of the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE PFA System as a first-line treatment for persistent atrial fibrillation (AF) compared to anti-arrhythmic drug therapy.

•Welcomed the presentation of data from the MANIFEST-17K registry of more than 17,000 patients treated with the FARAPULSE PFA System that reinforce the real world safety profile of the system.

•Enrollment commenced in the LAAOS-4 global research trial, which includes both the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device and WATCHMAN FLX Pro LAAC Device and explores if patients with AF at highest risk for stroke benefit from a combined LAAC and oral anticoagulation therapy.

•Received FDA approval for the TENACIO™ Pump, a new pump component for the AMS 700™ Inflatable Penile Prostheses, a treatment option for patients with erectile dysfunction.

•Completed the acquisition of Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the only U.S. FDA-cleared system, the Intracept® Intraosseous Nerve Ablation System, for vertebrogenic pain.

•Announced agreement to acquire Axonics, Inc., (Nasdaq: AXNX) a publicly traded medical technology company that offers differentiated devices to treat urinary and bowel dysfunction, subject to customary closing conditions.


1 Operational net sales growth excludes the impact of foreign currency fluctuations.
2 Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales.
3 Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union Medical Device Regulation (EU MDR) implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items.
4 Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. We have revised prior year amounts to conform to the current year's presentation.


Fourth quarter net sales by business and region:
Increase/(Decrease)
Three Months Ended December 31,Reported BasisImpact of Foreign Currency FluctuationsOperational BasisImpact of Recent Acquisitions / DivestituresOrganic Basis
(in millions)20232022
   Endoscopy$645 $571 12.9 %(0.7)%12.2 %(1.4)%10.8 %
   Urology527 477 10.5 %(0.5)%9.9 %— %9.9 %
   Neuromodulation269 249 8.0 %(0.5)%7.5 %(4.9)%2.6 %
MedSurg1,441 1,297 11.1 %(0.6)%10.5 %(1.6)%8.9 %
   Cardiology1,751 1,529 14.5 %(0.3)%14.2 %— %14.2 %
   Peripheral Interventions533 476 12.1 %0.1 %12.2 %(2.1)%10.2 %
Cardiovascular2,285 2,005 13.9 %(0.2)%13.8 %(0.5)%13.3 %
3,725 3,302 12.8 %(0.4)%12.5 %(0.9)%11.6 %
Other5
— (60)(100.0)%— %(100.0)%— %(100.0)%
Net Sales$3,725 $3,242 14.9 %(0.4)%14.5 %(0.9)%13.6 %
Increase/(Decrease)
Three Months Ended December 31,Reported BasisImpact of Foreign Currency FluctuationsOperational
 Basis
(in millions)20232022
U.S.$2,213 $1,986 11.4 %— %11.4 %
EMEA749 657 14.0 %(2.4)%11.6 %
APAC616 536 14.8 %2.2 %17.0 %
LACA148 122 20.8 %(6.2)%14.6 %
3,725 3,302 12.8 %(0.4)%12.5 %
Other5
— (60)(100.0)%— %(100.0)%
Net Sales$3,725 $3,242 14.9 %(0.4)%14.5 %
Emerging Markets4
$595 $511 16.3 %2.4 %18.7 %

5 In 2022, reflects unplanned reserves established in connection with the activation of the Italian government payback provision, aimed at rationalizing public spending and requiring medical device companies to pay back a portion of spend exceeding allocated health care budgets. In 2023, these sales reserves were allocated to reportable segments.

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions/divestitures are not prepared in accordance with GAAP.

Full year net sales by business and region:
Increase/(Decrease)
Year Ended
December 31,		Reported BasisImpact of Foreign Currency FluctuationsOperational BasisImpact of Recent Acquisitions / DivestituresOrganic Basis
(in millions)20232022
   Endoscopy$2,482 $2,221 11.7 %0.6 %12.3 %(1.2)%11.1 %
   Urology1,964 1,773 10.8 %0.4 %11.1 %— %11.1 %
   Neuromodulation976 917 6.4 %0.3 %6.7 %(1.3)%5.3 %
MedSurg5,422 4,911 10.4 %0.4 %10.8 %(0.8)%10.0 %
   Cardiology6,709 5,932 13.1 %0.9 %14.0 %(0.5)%13.6 %
   Peripheral Interventions2,110 1,899 11.1 %1.4 %12.6 %(1.6)%10.9 %
Cardiovascular8,819 7,831 12.6 %1.1 %13.7 %(0.7)%12.9 %
14,240 12,742 11.8 %0.8 %12.6 %(0.8)%11.8 %
Other5
— (60)(100.0)%— %(100.0)%— %(100.0)%
Net Sales$14,240 $12,682 12.3 %0.8 %13.1 %(0.8)%12.3 %
Increase/(Decrease)
Year Ended
December 31,		Reported BasisImpact of Foreign Currency FluctuationsOperational
 Basis
(in millions)20232022
U.S.$8,425 $7,632 10.4 %— %10.4 %
EMEA2,856 2,526 13.1 %(0.2)%12.9 %
APAC2,400 2,116 13.4 %5.7 %19.1 %
LACA560 469 19.3 %(2.4)%16.9 %
14,240 12,742 11.8 %0.8 %12.6 %
Other5
— (60)(100.0)%— %(100.0)%
Net Sales$14,240 $12,682 12.3 %0.8 %13.1 %
Emerging Markets4
$2,310 $1,968 17.3 %4.5 %21.9 %

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions/divestitures are not prepared in accordance with U.S. GAAP.
















Guidance for Full Year and First Quarter 2024

The company estimates net sales growth for the full year 2024, versus the prior year period, to be in a range of approximately 8.5 to 9.5 percent on a reported basis, and approximately 8 to 9 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.38 to $1.42 and estimates adjusted EPS, excluding certain charges (credits), of $2.23 to $2.27.

The company estimates net sales growth for the first quarter of 2024, versus the prior year period, to be in a range of approximately 7.5 to 9.5 percent on a reported basis, and approximately 7 to 9 percent on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.29 to $0.31 and estimates adjusted EPS, excluding certain charges (credits), of $0.50 to $0.52.


Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at
www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend," and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2024; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this press release.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.

Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
CONTACT:
Media:Emily AndersonInvestors:Lauren Tengler
617-515-2000 (office)508-683-4479 (office)
Media RelationsInvestor Relations
Boston Scientific CorporationBoston Scientific Corporation
Emily.Anderson2@bsci.comBSXInvestorRelations@bsci.com




BOSTON SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended
December 31,		Year Ended
December 31,
in millions, except per share data2023202220232022
Net sales$3,725 $3,242 $14,240 $12,682 
Cost of products sold1,146 1,011 4,345 3,956 
Gross profit2,579 2,231 9,896 8,727 
Operating expenses:
Selling, general and administrative expenses1,379 1,163 5,190 4,520 
Research and development expenses363 330 1,414 1,323 
Royalty expense12 13 46 47 
Amortization expense208 199 828 803 
Intangible asset impairment charges— — 58 132 
Contingent consideration net expense (benefit)14 (33)58 35 
Restructuring net charges (credits)19 6 69 24 
Litigation-related net charges (credits)— 131 (111)173 
Loss (gain) on disposal of businesses and assets— 22 — 22 
1,995 1,830 7,553 7,078 
Operating income (loss)584 402 2,343 1,649 
Other income (expense):
Interest expense(65)(64)(265)(470)
Other, net(14)58 (93)(38)
Income (loss) before income taxes505 396 1,985 1,141 
Income tax expense (benefit)1 256 393 443 
Net income (loss)$504 $140 $1,592 $698 
Preferred stock dividends— (14)(23)(55)
Net income (loss) attributable to noncontrolling interests(0)— (1)— 
Net income (loss) attributable to Boston Scientific common stockholders$504 $126 $1,570 $642 
Net income (loss) per common share - basic$0.34 $0.09 $1.08 $0.45 
Net income (loss) per common share - diluted$0.34 $0.09 $1.07 $0.45 
Weighted-average shares outstanding
Basic1,465.3 1,432.7 1,453.0 1,430.5 
Diluted1,476.9 1,442.4 1,463.5 1,439.7 




BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
Three Months Ended December 31, 2023
in millions, except per share data Gross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per Share
Reported$2,579 $1,995 $584 $(79)$505 $504 $— $504 $0.34 
Non-GAAP adjustments: 
Amortization expense— (208)208 — 208 178 — 176 0.12 
Acquisition/divestiture-related net charges (credits)9 (120)129 (0)129 54 — 54 0.04 
Restructuring and restructuring-related net charges (credits)22 (30)52 — 52 43 — 43 0.03 
Litigation-related net charges (credits)— — — — — (1)— (1)(0.00)
Investment portfolio net losses (gains)— — — (0)(0)2 — 2 0.00 
EU MDR implementation costs11 (5)16 — 16 14 — 14 0.01 
Deferred tax expenses (benefits)— — — — — 44 — 44 0.03 
Discrete tax items— — — — — (18)— (18)(0.01)
Adjusted$2,621 $1,631 $990 $(79)$911 $819 $— $817 $0.55 
Three Months Ended December 31, 2022
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(1)
Reported$2,231 $1,830 $402 $(6)$396 $140 $(14)$126 $0.09 
Non-GAAP adjustments:
Amortization expense— (199)199 — 199 175 — 175 0.12 
Acquisition/divestiture-related net charges (credits)24 (29)53 (44)9 59 — 59 0.04 
Restructuring and restructuring-related net charges (credits)16 (12)28 — 28 25 — 25 0.02 
Litigation-related net charges (credits)— (131)131 — 131 101 — 101 0.07 
Investment portfolio net losses (gains)— — — (38)(38)(32)— (32)(0.02)
EU MDR implementation costs13 (6)19 — 19 17 — 17 0.01 
Deferred tax expenses (benefits)— — — — — 42 — 42 0.03 
Discrete tax items— — — — — 129 — 129 0.09 
Adjusted$2,285 $1,452 $833 $(88)$745 $656 $(14)$642 $0.45 
(1) For the three months ended December 31, 2022 the effect of assuming the conversion of 5.50% Mandatory Convertible Preferred Stock, Series A (MCPS) into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income attributable to common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.















BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS
(Unaudited)
Year Ended December 31, 2023
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(2)
Reported$9,896 $7,553 $2,343 $(358)$1,985 $1,592 $(23)$1,570 $1.07 
Non-GAAP adjustments:
Amortization expense— (828)828 — 828 713 — 709 0.48 
Intangible asset impairment charges— (58)58 — 58 54 — 54 0.04 
Acquisition/divestiture-related net charges (credits)53 (314)367 6 373 352 — 352 0.24 
Restructuring and restructuring-related net charges (credits)77 (107)185 — 185 156 — 156 0.11 
Litigation-related net charges (credits)— 111 (111)— (111)(88)— (88)(0.06)
Investment portfolio net losses (gains)— — — 21 21 24 — 24 0.02 
EU MDR implementation costs47 (21)69 — 69 59 — 59 0.04 
Deferred tax expenses (benefits)— — — — — 155 — 155 0.11 
Discrete tax items— — — — — 8 — 8 0.01 
Adjusted$10,073 $6,335 $3,738 $(331)$3,407 $3,025 $(23)$2,999 $2.05 
Year Ended December 31, 2022
in millions, except per share dataGross ProfitOperating ExpensesOperating Income (Loss)Other Income (Expense)Income (Loss) Before Income TaxesNet Income (Loss)Preferred Stock DividendsNet Income (Loss) Attributable to Boston Scientific Common Stockholders
Impact per Share(2)
Reported$8,727 $7,078 $1,649 $(508)$1,141 $698 $(55)$642 $0.45 
Non-GAAP adjustments:
Amortization expense— (803)803 — 803 694 — 694 0.48 
Goodwill and Intangible asset impairment charges— (132)132 — 132 102 — 102 0.07 
Acquisition/divestiture-related net charges (credits)97 (206)303 (18)285 338 — 338 0.24 
Restructuring and restructuring-related net charges (credits)65 (45)110 — 110 96 — 96 0.07 
Litigation-related net charges (credits)— (173)173 — 173 133 — 133 0.09 
Investment portfolio net losses (gains)— — — (30)(30)(28)— (28)(0.02)
EU MDR implementation costs46 (25)71 — 71 62 — 62 0.04 
Debt extinguishment charges— — — 194 194 149 — 149 0.10 
Deferred tax expenses (benefits)— — — — — 140 — 140 0.10 
Discrete tax items— — — — — 129 — 129 0.09 
Adjusted$8,935 $5,694 $3,241 $(362)$2,880 $2,514 $(55)$2,459 $1.71 
(2) For the years ended December 31, 2023 and 2022, the effect of assuming the conversion of MCPS into shares of common stock was anti-dilutive, and therefore excluded from the calculation of EPS. Accordingly, GAAP net income and adjusted net income were reduced by cumulative Preferred stock dividends, as presented in our unaudited consolidated statements of operations, for purposes of calculating net income attributable to common stockholders. On June 1, 2023, all outstanding shares of MCPS automatically converted into shares of common stock.
An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document.








BOSTON SCIENTIFIC CORPORATION
Q1 and FY 2024 GUIDANCE RECONCILIATIONS
(Unaudited)

Net Sales
Q1 2024 EstimateFull Year 2024 Estimate
(Low)(High)(Low)(High)
Reported growth7.5 %9.5 %8.5 %9.5 %
Impact of foreign currency fluctuations1.0 %1.0 %0.5 %0.5 %
Operational growth8.5 %10.5 %9.0 %10.0 %
Impact of acquisitions/divestitures(1.5)%(1.5)%(1.0)%(1.0)%
Organic growth7.0 %9.0 %8.0 %9.0 %

Earnings per Share
Q1 2024 EstimateFull Year 2024 Estimate
(Low)(High)(Low)(High)
GAAP results$0.29 $0.31 $1.38 $1.42 
Amortization expense0.12 0.12 0.48 0.48 
Acquisition/divestiture-related net charges (credits)0.03 0.03 0.10 0.10 
Restructuring and restructuring-related net charges (credits)0.02 0.02 0.11 0.11 
Other adjustments0.04 0.04 0.16 0.16 
Adjusted results$0.50 $0.52 $2.23 $2.27 





Use of Non-GAAP Financial Measures

To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share, we exclude certain charges (credits) from GAAP net income and GAAP net income attributable to Boston Scientific common stockholders, which include amortization expense, goodwill and intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio gains and losses, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, debt extinguishment charges, deferred tax expenses (benefits) and discrete tax items. Amounts are presented after-tax using the company's effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 740-270-30, “General Methodology and Use of Estimated Annual Effective Tax Rate.” Please refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations in any Quarterly Report on Form 10-Q that we have filed or will file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share are GAAP net income (loss), GAAP net income (loss) attributable to Boston Scientific common stockholders and GAAP net income (loss) per common share – diluted, respectively.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior periods. To calculate organic net sales growth rates, we also remove the impact of acquisitions and divestitures with less than a full period of comparable net sales. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to


further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders, adjusted net income (loss) per share, operational net sales growth rates and organic net sales growth rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

EX-101.SCH 3 bsx-20240131.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bsx-20240131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 bsx-20240131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Class of Stock [Domain] Class of Stock [Domain] City Area Code City Area Code Entities [Table] Entities [Table] Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Senior Note due 2027 [Member] Senior Note due 2027 [Member] Senior Note due 2027 [Member] Entity Information [Line Items] Entity Information [Line Items] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Common Stock [Member] Common Stock [Member] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Class of Stock [Axis] Class of Stock [Axis] Local Phone Number Local Phone Number Written Communications Written Communications Cover page. Cover [Abstract] Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 bsx-20240131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 imagea.jpg begin 644 imagea.jpg MB5!.1PT*&@H -24A$4@ ! H "6" 8 !73VH' 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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�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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover Document
Jan. 31, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Jan. 31, 2024
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 1-11083
Entity Tax Identification Number 04-2695240
Entity Address, Address Line One 300 Boston Scientific Way
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752-1234
City Area Code 508
Local Phone Number 683-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000885725
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol BSX
Security Exchange Name NYSE
Senior Note due 2027 [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 0.625% Senior Notes due 2027
Trading Symbol BSX27
Security Exchange Name NYSE

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports bsx-20240131.htm bsx-20240131.xsd bsx-20240131_def.xml bsx-20240131_lab.xml bsx-20240131_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bsx-20240131.htm": { "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20240131", "dts": { "inline": { "local": [ "bsx-20240131.htm" ] }, "schema": { "local": [ "bsx-20240131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "definitionLink": { "local": [ "bsx-20240131_def.xml" ] }, "labelLink": { "local": [ "bsx-20240131_lab.xml" ] }, "presentationLink": { "local": [ "bsx-20240131_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 25 }, "report": { "R1": { "role": "http://www.bostonscientific.com/role/CoverDocument", "longName": "0000001 - Document - Cover Document", "shortName": "Cover Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240131.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bsx-20240131.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockMember", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitiesTable", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "bsx_SeniorNotedue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bostonscientific.com/20240131", "localname": "SeniorNotedue2027Member", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Note due 2027 [Member]", "label": "Senior Note due 2027 [Member]", "documentation": "Senior Note due 2027 [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0000885725-24-000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-24-000011-xbrl.zip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bsx-20240131_htm.xml IDEA: XBRL DOCUMENT 0000885725 2024-01-31 2024-01-31 0000885725 us-gaap:CommonStockMember 2024-01-31 2024-01-31 0000885725 bsx:SeniorNotedue2027Member 2024-01-31 2024-01-31 0000885725 false 8-K 2024-01-31 BOSTON SCIENTIFIC CORPORATION DE 1-11083 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 false false false false Common Stock, $0.01 par value per share BSX NYSE 0.625% Senior Notes due 2027 BSX27 NYSE false